drugset / Trial / NCT00625898
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
Phase 3
Terminated
3509 enrolled
NSABP Foundation Inc
Cancer International Research Group (CIRG) · collabGenentech, Inc. · collabHoffmann-La Roche · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The trial will determine the value of adding bevacizumab to chemotherapy plus trastuzumab in patients with resected node-positive or high risk node-negative, HER2-positive breast cancer.
Timeline
- Start
- 2008-04
- Primary completion
- 2013-06
- Completion
- 2014-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Carboplatin | Small molecule | 6 unknown | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | Intravenous |
| Background | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Background | Docetaxel | Small molecule | 100 mg/m2 | Intravenous |
| Background | Epirubicin | Small molecule | 90 mg/m2 | Intravenous |
| Background | Trastuzumab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Background | fluorouracil | Small molecule | 600 mg/m2 | Intravenous |